BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infectedpatients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.
Authors: G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev Journal: Bull World Health Organ Date: 1969 Impact factor: 9.408
Authors: J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick Journal: J Clin Microbiol Date: 1993-02 Impact factor: 5.948
Authors: P Nunn; D Kibuga; S Gathua; R Brindle; A Imalingat; K Wasunna; S Lucas; C Gilks; M Omwega; J Were Journal: Lancet Date: 1991-03-16 Impact factor: 79.321
Authors: M Hawken; P Nunn; S Gathua; R Brindle; P Godfrey-Faussett; W Githui; J Odhiambo; B Batchelor; C Gilks; J Morris Journal: Lancet Date: 1993-08-07 Impact factor: 79.321
Authors: J H Perriëns; R L Colebunders; C Karahunga; J C Willame; J Jeugmans; M Kaboto; Y Mukadi; P Pauwels; R W Ryder; J Prignot Journal: Am Rev Respir Dis Date: 1991-10
Authors: A N Ackah; D Coulibaly; H Digbeu; K Diallo; K M Vetter; I M Coulibaly; A E Greenberg; K M De Cock Journal: Lancet Date: 1995-03-11 Impact factor: 79.321
Authors: Ibrahim Sendagire; Maarten Schim Van der Loeff; Andrew Kambugu; Joseph Konde-Lule; Frank Cobelens Journal: PLoS One Date: 2012-05-02 Impact factor: 3.240